Sight Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGHT research report →
Range $7 – $14
Price Chart
About the company
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients.
- CEO
- Paul Badawi
- IPO
- 2021
- Employees
- 186
- HQ
- Menlo Park, CA, US
Get TickerSpark's AI analysis on SGHT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $565.79M
- P/E
- -19.64
- PEG
- -0.33
- P/S
- 6.40
- P/B
- 11.42
- EV/EBITDA
- -21.75
- Div Yield
- 0.00%
- Gross Margin
- 87.74%
- Op Margin
- -29.52%
- Net Margin
- -32.13%
- ROE
- -51.66%
- ROIC
- -28.59%
Latest fiscal year · YoY change
- Revenue
- $77.36M-3.1%
- Gross Profit
- $66.67M-2.4%
- Op Income
- $-37,099,000
- Net Income
- $-38,426,000+25.4%
- EPS
- $-0.74+28.2%
- OCF Growth
- -32.9%
- FCF Growth
- -31.6%
- 52W High
- $11.60
- 52W Low
- $3.38
- 50D MA
- $9.21
- 200D MA
- $6.29
- Beta
- 2.40
- RSI (14)
- 54
- Avg Volume
- 313.51K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sight Sciences posted record Q3 revenue with 25% growth, improved cash burn, and raised full-year 2026 revenue guidance while keeping expenses in check.· November 4, 2026
- Record Q3 revenue of $24.9 million grew 25% year over year, the third straight quarter of double-digit growth.
- IDE revenue reached a record $3.9 million, up 45% sequentially, with ordering accounts rising to 222 and utilization increasing to 21 SmartLids per account.
- IG revenue was $21 million, up 7% year over year, with active accounts at an all-time high and coverage expanding through Aetna.
- Gross margin held at 86% overall; IDE gross margin improved sharply to 79% from 38% a year ago.
- Management raised full-year 2026 revenue guidance to $92 million-$93 million and kept adjusted operating expense guidance at $92 million-$94 million.
Third quarter revenue was a record $24.9 million, up 25% year over year. IG revenue was $21 million, up 7% versus the prior-year period, and IDE revenue was a record $3.9 million, up 45% sequentially from Q2. Gross margin was 86% overall, with IG gross margin at 87% and IDE gross margin at 79% versus 38% a year ago. Net loss was $6.8 million, or $0.12 per share, versus $8.2 million and $0.16 per share in the prior-year period. Cash and cash equivalents ended at $77.4 million, cash used in the quarter was $2.4 million versus $9.1 million a year ago, and debt was $40 million excluding unamortized discount and debt issuance costs. For 2026, the company raised total revenue guidance to $92 million-$93 million from $88 million-$92 million, including IDE revenue of about $12 million and IG revenue of $80 million-$81 million, while maintaining adjusted operating expense guidance at $92 million-$94 million.
Paul Badawi emphasized that Sight Sciences is becoming a broader interventional eye care platform, centered on the overlap between glaucoma and dry eye customers and procedures. He highlighted the new TearCare FDA label expansion as validation of the company’s approach and pointed to OMNI Ultra and the IX strategy as long-term growth drivers. His tone was confident and upbeat, but grounded in execution, repeatedly stressing earlier intervention, customer adoption, and scalable commercial leverage.
Jim Rodberg focused on the operating leverage in the model: revenue rose 25% while adjusted operating expenses were $24 million, up 21% year over year, and year-to-date revenue grew 19% while adjusted OpEx declined 2%. He pointed to improved cash burn, with quarterly cash use of $2.4 million and year-to-date cash usage of $14.6 million, and said the company remains well positioned to reach cash flow breakeven without raising additional equity. He also noted the debt maturity extension, with the interest-only period pushed to August 2027, as a prudent capital management move that gives additional optionality.
Analysts pressed management on why full-year guidance still implies a relatively modest Q4 step-up, and management responded that they are being cautious, especially in IDE, because the business is still early in its market development and they do not want to get ahead of access and seasonality. Questions also focused on TearCare utilization, the label expansion, payer discussions, and the stand-alone glaucoma opportunity; management said utilization still has room to grow, the label helps reinforce the product’s value proposition, and payer discussions are supported by clinical, economic, and claims data but timing remains uncertain. On stand-alone MIGS, management said the key is moving from education to workflow activation inside practices, including staff and administrator engagement.
The call showed accelerating execution in both segments, with IDE growing quickly from a small base and IG continuing to expand on the back of record active accounts and the OMNI Ultra launch. Management also sounded confident that the TearCare label expansion and improving payer access could support a larger reimbursed market over time. The company improved cash burn materially while still investing in growth, which supports the argument that revenue can scale without proportional expense growth.
Management’s own guidance suggests near-term conservatism, especially in IDE, because TearCare remains early in its market development and broader payer coverage is not yet established. IG growth is solid but not explosive, and management acknowledged that stand-alone MIGS is still an underpenetrated market that requires more practice-level activation work. Debt remains on the balance sheet, and while management is comfortable with liquidity, they are still targeting cash flow breakeven rather than already generating it.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 64.8%
- Shares Outstanding
- 55.58M
- Float Shares
- 36.01M
of shares held by institutions
116 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Long Focus Capital Management, LLC | 3.84M | ▲ 250.00K |
| Blackrock, Inc. | 3.36M | ▲ 278.10K |
| Pathstone Holdings, LLC | 2.19M | ▲ 507.54K |
| Vanguard Group Inc | 1.95M | ▲ 41.95K |
| Vanguard Capital Management LLC | 1.64M | ▲ 61.56K |
| Geode Capital Management, LLC | 979.09K | ▲ 20.53K |
| B Group, Inc. | 970.00K | 0 |
| Acadian Asset Management LLC | 844.12K | ▲ 37.54K |
| State Street Corp | 840.63K | ▲ 5.18K |
| Aqr Capital Management LLC | 397.56K | ▲ 259.04K |
| Dimensional Fund Advisors LP | 370.75K | ▼ 12.76K |
| Northern Trust Corp | 343.58K | ▲ 11.27K |
Held by 110 ETFs
Biggest fund positions in SGHT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Taylor Brenton | sell | 20,685 |
| Oct 2, 26 | Taylor Brenton | sell | 2,988 |
| Oct 2, 26 | Bauerlein Alison | sell | 25,260 |
| Oct 2, 26 | Rodberg James | sell | 7,208 |
| Oct 1, 26 | Badawi David | sell | 7,797 |
| Oct 1, 26 | Badawi Paul | sell | 29,653 |
| Aug 10, 26 | Rashid Kashif | other | 181,818 |
| Aug 10, 26 | Rashid Kashif | other | 0 |
| Jul 6, 26 | HAYDEN JEREMY B. | sell | 12,733 |
| Jul 2, 26 | Rodberg James | sell | 6,902 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SGHT coverage
Recent articles, reports, and earnings notes.
No research on SGHT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SGHT report →Sight Sciences, Inc. (SGHT) is a Great Momentum Stock: Should You Buy?
zacks.com · Nov 12
Sight Sciences, Inc. (NASDAQ:SGHT) Stock Now Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net · Nov 6
Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
globenewswire.com · Nov 5
What Sight Sciences (SGHT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 4
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 4
Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.